UK markets close in 7 hours 54 minutes

GenSight Biologics S.A. (GSGTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.75000.0000 (0.00%)
At close: 10:32AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 214.72M
Enterprise value 172.33M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)19.76
Price/book (mrq)6.19
Enterprise value/revenue 62.35
Enterprise value/EBITDA -6.15

Trading information

Stock price history

Beta (5Y monthly) 2.78
52-week change 3-40.62%
S&P500 52-week change 3-2.16%
52-week high 39.3500
52-week low 34.5000
50-day moving average 34.7500
200-day moving average 35.3261

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 546.16M
Implied shares outstanding 6N/A
Float 830.81M
% held by insiders 114.80%
% held by institutions 136.99%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-658.59%

Management effectiveness

Return on assets (ttm)-38.76%
Return on equity (ttm)-171.90%

Income statement

Revenue (ttm)5.08M
Revenue per share (ttm)0.11
Quarterly revenue growth (yoy)-38.20%
Gross profit (ttm)7.71M
EBITDA -33.47M
Net income avi to common (ttm)-31.03M
Diluted EPS (ttm)-0.6660
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)24.15M
Total cash per share (mrq)0.52
Total debt (mrq)16.09M
Total debt/equity (mrq)502.34
Current ratio (mrq)1.88
Book value per share (mrq)0.35

Cash flow statement

Operating cash flow (ttm)-23.61M
Levered free cash flow (ttm)-21.55M